🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥 Just out in Journal of the @NCCN — mentoring Suriya Baskar on this project (and others) has been one of the most fulfilling experiences of my career 🙌 We take on a rare care delivery topic relevant to the care of patients with #NeuroendocrineTumors 📊 What we found in >7,000 inpatient

Recognizing the Rising Stars from ASCO 2025 at Times Square. This list is based on early-career oncologists with high posting volume and the highest increase in views on X. Nicholas Hornstein | Diego A. Díaz García | Roberto Borea, MD | Jose C. Tapia | Oriol Mirallas MD | Michael Serzan, MD | Charles Jiang MD, MPH |

Thanks for the recognition! It’s been a great experience joining X, and now I can say I’ve been on a Times Square sign.

🚨 New data on FGFR2b in gastric & GEJ cancer! Kohei shitara et al in ESMO Open A single-institution cohort (N=492): 🧬 FGFR2b overexpression (any 2+/3+): • Seen in 15.4% of all patients • In recent samples (≤1.5 yrs old): 29.8% 🔍 Limited biomarker overlap: • ~54% of

An inspiring day at the 2025 Cold Spring Harbor Laboratory Cancer Center Symposium. 🧬 From senescence & reprogramming to AI-powered genomics & macrophage biology—basic science is pushing boundaries. Grateful to connect with faculty & trainees, including a standout keynote from Dr. Miriam Merad on

To chemo-IO in adjuvant MSI-H CRC, or to IO alone, the question, that is.

I’m seeing too many patients that are “too young” to have cancer. I’m self-referring this week.

Had a conversation with someone outside of healthcare recently who was shocked by how long it takes to run clinical trials in the U.S (not to mention expensive). I tried to explain—it’s not just the science. It’s the infrastructure. Every site needs dozens of personnel, many of

Excited to share our new publication on liver-directed therapies for colorectal liver metastases. Thank you to my co-authors & ASCO for the opportunity to run this educational session! Nicholas Hornstein Northwell Health COLONTOWN Colorectal Cancer Alliance ascopubs.org/doi/10.1200/ED…

Bob Roth Udhayvir Grewal Tim Brown, MD MSCE I spent way too long typing this out on my phone for a reply but: 1.Incentivize Use of Centralized Review Systems •Encourage or require use of central IRBs, PRMCs, and contracting offices—especially for multi-site trials. •Tie use of centralized platforms to funding mechanisms

Had an opportunity to chat about significant GI Abstracts presented at ASCO 2025 with Udhayvir Grewal and Tim Brown, MD MSCE The year of the poop tube! ASCO® 2025 Summary: Noteworthy GI Abstracts Recap and Clinical Application | VuMedi vumedi.com/video/ascor-20… via @vumedi

Various liver-directed therapies are revolutionizing the treatment approach and improving clinical outcomes for patients with unresectable colorectal liver metastases. Read more in #ASCOEdBook: bit.ly/4lbpJ5L Nicholas Hornstein @Faucejo #gicsm #crcsm

The OncoAlert🚨Newsletter Now Out !! Covering Jun 12-19, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ✅Association of HRR Alterations With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer ✅Comorbidity Burden and Effectiveness of

Excited to join an upcoming virtual tumor board on Histotripsy for Liver Tumors, hosted by HistoSonics. Alongside Mikhail Silk (NYU) and David Kwon (Cleveland Clinic), we’ll discuss some cases, clinical evidence, and future research directions. I'll be bringing the medical

📢 Press release drop—interpret with appropriate caution. Exelixis reports that zanzalintinib + atezolizumab improved overall survival vs regorafenib in the Phase 3 STELLAR-303 trial for third-line MSS metastatic colorectal cancer. This isn’t the highest bar—survival in this

Cheers to a very productive Gut Onc Lab meeting. Cool ideas and great progress. Excited for what’s to come. #GIOnc #DreamTeam Nicholas Hornstein Tim Brown, MD MSCE Deepak Vadehra Udhayvir Grewal Sidharth Mahajan, MD Sawyer Bawek, DO 💯😎

🚨 Practice-Changing Data in HER2+ Gastric Cancer (May 31 Publication, but now with a video!) In the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan (T-DXd) significantly improved overall survival vs ramucirumab + paclitaxel in the 2nd-line setting for patients with